Bharat Book Bureau provides the report, on “Frontier Pharma: Parkinson’s Disease - Identifying and Commercializing First-in-Class Innovation”. In this report main motor symptoms are tremors, bradykinesia and rigidity, although symptoms vary between individuals. https://www.bharatbook.com/healthcare-market-research-reports-201860/frontier-pharma-parkinson-disease-identifying-commercializing1.html
A highly active pancreatic cancer pipeline contains an array of products with varying molecule types and mechanisms of action, which provides a striking contrast to the current, chemotherapy dominated, market. Within the pipeline, there are 185 products that act on a first-in-class molecular target, representing 52% of the total pancreatic cancer pipeline products that have a disclosed molecular target
The report analyzes innovation in prostate cancer, in the context of the overall pipeline and current market landscape. In addition, it analyzed the deals landscape surrounding first-in-class products in prostate cancer, and pinpoints opportunities for in-licensing. For Further Details : http://www.bigmarketresearch.com/frontier-pharma-prostate-cancer-identifying-and-commercializing-first-in-class-innovation-market
This Report provided by 24 Market Reports is about, Immunology is a large therapy area characterized by disorders of the immune system – specifically an aberrant immune response against healthy tissues present in the body, leading to chronic or acute inflammation.
Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. More pertinently, the degree and proportion of breakthrough innovations is significant. The Research analysis identified 59 first-in-class programs in the asthma pipeline, acting on 43 first-in-class molecular targets, accounting for 23% of all products with a disclosed molecular target and reflective of the high degree of innovation in this indication.
Research Beam added a report on “Frontier Pharma Parkinsons Disease - Identifying and Commercializing First-in-Class Innovation” Enquiry about report: http://www.researchbeam.com/frontier-pharma-parkinsons-disease-identifying-and-commercializing-first-in-class-innovation-market/enquire-about-report
The breast cancer pipeline is the largest in the pharmaceutical industry with 815 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. More pertinently, the degree and proportion of breakthrough innovations in this pipeline is exceptional; GBI Research analysis identified 253 first-in-class programs in the breast cancer pipeline, acting on 176 first-in-class molecular targets. Browse complete report with TOC: http://www.reportsandintelligence.com/frontier-pharma-breast-cancer-identifying-and-commercializing-first-in-class-innovation-market
The active pain pipeline is populated by 796 products across all stages of development, which exhibit a highly diverse range of molecular targets. GBI Research’s analyses identified 122 first-in-class programs in active development, constituting 13.6% of the pipeline and acting on 65 first-in-class molecular targets, indicating a high degree of innovation. Enquiry @ http://www.researchbeam.com/frontier-pharma-pain-identifying-and-commercializing-first-in-class-innovation-market/enquire-about-report
Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. More pertinently, the degree and proportion of breakthrough innovations is significant. GBI Research analysis identified 59 first-in-class programs in the asthma pipeline, acting on 43 first-in-class molecular targets, accounting for 23% of all products with a disclosed molecular target and reflective of the high degree of innovation in this indication. Enquiry @ http://www.researchbeam.com/frontier-pharma-asthma-identifying-and-commercializing-first-in-class-innovation-market/enquire-about-report
The Parkinsons disease (PD) pipeline currently has 302 products in active development across all stages, but a stark contrast between the mechanisms of action employed in the current market and the pipeline is evident.
The liver cancer pipeline contains 238 products in active development, approximately 47% of which are first-in-class. The percentage of the pipeline devoted to innovative products is considerably larger than both the industry and oncology average, which is a promising sign for novel therapeutics reaching the liver cancer market. Enquiry @ http://www.researchbeam.com/frontier-pharma-liver-cancer-identifying-and-commercializing-first-in-class-innovation-market/enquire-about-report
The active Alzheimer’s Disease (AD) pipeline is populated with 583 products, with a highly diverse range of molecular targets. GBI Research analysis revealed a high degree of innovation in this indication, with 46% of the pipeline being first-in-class products, acting on over 40 first-in-class molecular targets. In addition, the pipeline is characterized by the strong presence of therapies that target multiple components implicated in the amyloid cascade, several molecular targets of which are known to trigger familial AD.
The active Alzheimer’s Disease (AD) pipeline is populated with 583 products, with a highly diverse range of molecular targets. For more details : http://goo.gl/WVUmG0
Non-Hodgkin Lymphoma (NHL) can be seen as a collection of up to 60 smaller subtypes of malignant lymphoid disease, defined by distinct morphological, cytogenetic and immunophenotypic characteristics that can be broadly classified as either indolent or aggressive disease. The slow growing nature of the former means that first-line treatment for diagnosed patients can be delayed, an option not commonly recommended for aggressive disease. Enquiry @ http://www.researchbeam.com/frontier-pharma-innovative-licensing-opportunities-in-non-hodgkin-lymphoma-market/enquire-about-report
The Parkinsons disease (PD) pipeline currently has 302 products in active development across all stages, but a stark contrast between the mechanisms of action employed in the current market and the pipeline is evident. Where the market relies on symptomatic treatments that target neuromodulatory receptors, the pipeline shows a diverse range of neuroprotective therapies targeting dysfunctional disease processes. See Full Report : http://bit.ly/14ZURze
The oncology therapy area comprises a large and diverse range of indications, encompassing virtually all sites and tissues in the human body. These indications are the leading cause of death in economically developed countries and the second-leading cause of death in developing countries and present a major global health burden. Enquiry @ http://www.researchbeam.com/frontier-pharma-versatile-innovation-in-oncology-identifying-and-commercializing-versatile-first-in-class-innovation-market/enquire-about-report
The Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) pipeline consists of 84 molecules across all stages of development. GBI Researchs analysis revealed a high degree of innovation and diversity in this indication, with 70% of the pipeline being first-in-class products, acting on 13 first-in-class targets. Enquiry @ http://www.researchbeam.com/frontier-pharma-duchenne-muscular-dystrophy-and-becker-muscular-dystrophy-identifying-and-commercializing-first-in-class-innovation-market/enquire-about-report
The prostate cancer pipeline is among the largest in the pharmaceutical industry with 484 products in active development across all stages. For More Details: http://goo.gl/cIMtf5
The report examines and analyzes innovation in global parkinsons disease market in the context of the overall pipeline and current market landscape. It provides a brief introduction to parkinson's disease pathophysiology including symptoms and an overview of pharmacotherapy. Browse full report @ http://bit.ly/14ZURze
The “Parkinsons disease” (PD) pipeline currently has 302 products in active development across all stages, but a stark contrast between the mechanisms of action employed in the current market and the pipeline is evident. For More Details: http://goo.gl/a4BN91
We can help Chinese Bio Pharma Industry by ... Hosting Chinese gusts in SD/CA/USA ... An annual book series 'Frontier of Biotechnology and Pharmaceuticals' since 2000 ...
Product Supply. Biotechnology Global Supply Chain Management. Science For ... this improved certainty, comes the imperative for flawless commercial operations ...
GBI Research has released the pharma report: “Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation”, which identifies and assesses first-in-class innovation in the psoriasis development pipeline. Get more about this report at: http://www.bigmarketresearch.com/frontier-pharma-psoriasis-identifying-and-commercializing-first-in-class-innovation-market
Frontier Pharma: Transplantation Therapeutics-A Highly Innovative Pipeline with a Range of Adaptive and Innate Immune-Targeting Programs Focusing on Graft-Versus-Host Disease and Kidney Transplantation
Research Beam added a report on “Chronic Obstructive Pulmonary Disease (COPD) - Identifying and Commercializing First-in-Class Innovation” Enquiry about report: http://www.researchbeam.com/frontier-pharma-chronic-obstructive-pulmonary-disease-copd-identifying-and-commercializing-first-in-class-innovation-market/enquire-about-report
Big Market Research presents this report which covers and includes a brief introduction to pain, including the different subtypes of pain, pathophysiology, and overview of pharmacotherapy and treatment algorithms. Read The Full Report On : http://www.bigmarketresearch.com/frontier-pharma-pain-identifying-and-commercializing-first-in-class-innovation-market
The report will enable business development and enable marketing executives to strategize their product launches by allowing them to understand the focal shifts in molecular targets in the NSCLC pipeline For Further Details : http://www.bigmarketresearch.com/frontier-pharma-non-small-cell-lung-cancer-identifying-and-commercializing-first-in-class-innovation-market
The report analyzes innovation in PD in the context of the overall pipeline and current market landscape. It also analyzes the deals landscape surrounding first-in-class products and pinpoints in-licensing opportunities. For Further Details : http://www.bigmarketresearch.com/frontier-pharma-parkinsons-disease-identifying-and-commercializing-first-in-class-innovation-market
Big Market Research presents this report which features an analysis of granted patent applications in the liver cancer market, which was used as an indication of innovation at the earliest stage of product development. Read The Complete Report On : http://www.bigmarketresearch.com/frontier-pharma-liver-cancer-identifying-and-commercializing-first-in-class-innovation-market
Big Market Research presents this report which covers and includes a brief introduction to AD, including symptoms, pathophysiology, and overview of pharmacotherapy and treatment algorithms,the changing molecular target landscape between market and pipeline and particular focal points of innovation in the pipeline Read The Complete Report On : http://www.bigmarketresearch.com/frontier-pharma-alzheimers-disease-identifying-and-commercializing-first-in-class-innovation-market
Large and Diverse Pipeline The liver cancer pipeline contains 238 products in active development, approximately 47% of which are first-in-class. The percentage of the pipeline devoted to innovative products is considerably larger than both the industry and oncology average, which is a promising sign for novel therapeutics reaching the liver cancer market. Get more about this report at: http://www.bigmarketresearch.com/frontier-pharma-liver-cancer-identifying-and-commercializing-first-in-class-innovation-market
The active pain pipeline is populated by 796 products across all stages of development, which exhibit a highly diverse range of molecular targets. GBI Research’s analyses identified 122 first-in-class programs in active development, constituting 13.6% of the pipeline and acting on 65 first-in-class molecular targets, indicating a high degree of innovation. Get more about this report at: http://www.bigmarketresearch.com/frontier-pharma-pain-identifying-and-commercializing-first-in-class-innovation-market
Detailed report at: http://www.reportsandintelligence.com/frontier-pharma-asthma-identifying-and-commercializing-first-in-class-innovation-reports-market Based on existing market products, the compounds that are witnessing breakthrough are highly diverse in there mode of action. Drug companies can take this as an opportunity and work on floating products that can offer advantage in various geographies. As per a research, 50 first-in-class programs are identified in the asthma market. The programs are focused towards targeting 43 first-in-class molecular targets. Almost 23% of the products with disclosed molecular targets are expected to witness the results of the latest innovations in the asthma market. Web link: http://www.reportsandintelligence.com/
The breast cancer pipeline is the largest in the pharmaceutical industry with 815 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. See Full Report @ bit.ly/1zECLMf
PetLife Pharmaceuticals, Inc. (PetLife Pharma) has developed and is launching a new generation of potentiated veterinary cancer medications and nutraceuticals.
Update: Hip Arthroscopy New Frontiers Marc R. Safran, MD Professor, Orthopaedic Surgery Associate Director, Sports Medicine Team Physician Stanford University
2002 - NRC report 'Small Wonders, Endless Frontiers' recommends that OSTP ... Source: Small Times Media (2004) 19. Where do we stand? TAG identified areas of ...
The Systemic Lupus Erythematosus (SLE) drug market is currently under-served by non-generic, targeted therapies. Whilst the only Food and Drug Administration (FDA)-approved biologic, Benlysta (belimumab), generated sales of $111m in 2012, there is little evidence that the drug’s performance is significantly superior to other B-cell targeted therapies such as Rituxan (rituximab), which is often used off-license to treat refractory SLE patients. Complete report is available @ http://www.rnrmarketresearch.com/frontier-pharma-systemic-lupus-erythematosus-identifying-and-commercializing-first-in-class-innovation-market-report.html .
Ovarian cancer is the sixth most common cancer in females and it also has the highest mortality rate of gynecological cancers. The five-year survival rate is approximately 45%, although the disease is ultimately fatal in the majority of patients due to a high rate of recurrence.
Ovarian cancer is the sixth most common cancer in females and it also has the highest mortality rate of gynecological cancers. The five-year survival rate is approximately 45%, although the disease is ultimately fatal in the majority of patients due to a high rate of recurrence.
Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease, affecting around 7.4 million people worldwide. It is caused by the progressive loss of dopamine-producing neurons in the substantia nigra within the basal ganglia.
Market Reports on India present the latest report on “India Vanilla Market”, this report focuses on sales, market share and growth rate of Vanilla in each application, split by applications/end use industries.
Download Free Research Report PDF @ http://bit.ly/36LLQcs #PureVanilla #MarketAnalysis Pure Vanilla report researches the worldwide its market size (value, capacity, production and consumption) in key regions like North America, Europe, China and Japan. Full Report Url - http://bit.ly/36LLQcs
Asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape.
The prostate cancer pipeline is among the largest in the pharmaceutical industry with 484 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. More pertinently, the degree and proportion of breakthrough innovations in this pipeline is exceptional; The Research analysis identified 174 first-in-class programs in the prostate cancer pipeline, acting on 122 first-in-class molecular targets. This accounts for some 36% of all products with a disclosed molecular target and is reflective of the high degree of innovation in this indication.
The Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) pipeline consists of 84 molecules across all stages of development. The analysis revealed a high degree of innovation and diversity in this indication, with 70% of the pipeline being first-in-class products, acting on 13 first-in-class targets.
Pancreatic cancer is the 12th most common cancer globally, and the fourth most fatal, with a mortality rate of 10.9 deaths per 100,000 people per year.
Obesity is a major growing health concern around the world. In most markets, a person is considered obese if their Body Mass Index (BMI) exceeds 30 kilograms per square meter (kg/m2), calculated by dividing body mass in kilograms by height in meters squared.
Non-Hodgkin Lymphoma (NHL) can be seen as a collection of up to 60 smaller subtypes of malignant lymphoid disease, defined by distinct morphological, cytogenetic and immunophenotypic characteristics that can be broadly classified as either indolent or aggressive disease.
The oncology therapy area comprises a large and diverse range of indications, encompassing virtually all sites and tissues in the human body. These indications are the leading cause of death in economically developed countries and the second-leading cause of death in developing countries and present a major global health burden. Across the pharmaceutical industry as a whole, the oncology pipeline is far larger than any other therapy area, with 6,484 products in active development across all oncology indications, and 2,084 first-in-class products in development across all stages.
The active pain pipeline is populated by 796 products across all stages of development, which exhibit a highly diverse range of molecular targets. The Research’s analyses identified 122 first-in-class programs in active development, constituting 13.6% of the pipeline and acting on 65 first-in-class molecular targets, indicating a high degree of innovation. This is in stark contrast to the pain therapeutics market, which has been largely characterized by only incremental product innovation over the last decade, as most market segments continue to be dominated by long-established active pharmaceutical ingredients and the concomitant mechanisms of action.